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Abstract
AIM: To analyze whether pancreaticoduodenectomy 
with simultaneous resection of tumor-involved vessels 
is a safe approach with acceptable patient survival.
METHODS: Between January 2001 and March 2012, 
136 patients received pancreaticoduodenectomy for 
adenocarcinoma at our hospital. Seventy-eight patients 
diagnosed with pancreatic head carcinoma were in-
cluded in this study. Among them, 46 patients received 
standard pancreaticoduodenectomy (group 1) and 
32 patients received pancreaticoduodenectomy with 
simultaneous resection of the portal vein or the supe-
rior mesenteric vein or artery (group 2) followed by 
reconstruction. The immediate surgical outcomes and 
survivals were compared between the groups. Fifty-five 
patients with unresectable adenocarcinoma of the pan-
creas without liver metastasis who received only bypass 
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operations (group 3) were selected for additional sur-
vival comparison.
RESULTS: The median ages of patients were 67 years 
(range: 37-82 years) in group 1, and 63 years (range: 
35-86 years) in group 2. All group 2 patients had resec-
tion of the portal vein or the superior mesenteric vein 
and three patients had resection of the superior mes-
enteric artery. The pancreatic fistula formation rate was 
21.7% (10/46) in group 1 and 15.6% (5/32) in group 
2 (P  = 0.662). Two hospital deaths (4.3%) occurred 
in group 1 and one hospital death (3.1%) occurred 
in group 2 (P  = 0.641). The one-year, three-year and 
five-year overall survival rates in group 1 were 71.1%, 
23.6% and 13.5%, respectively. The corresponding 
rates in group 2 were 70.6%, 33.3% and 22.2% (P  
= 0.815). The one-year survival rate in group 3 was 
13.8%. Pancreaticoduodenectomy with simultaneous 
vascular resection was safe for pancreatic head adeno-
carcinoma.
CONCLUSION: The short-term and survival outcomes 
with simultaneous resection were not compromised 
when compared with that of standard pancreaticoduo-
denectomy.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Whipple operation with vascular reconstruction 
is considered one of the most difficult operations with 
high morbidity. In this paper, we demonstrate that this 
complicated surgery can be performed in low-volume 
centers where a high volume of other complicated liver 
surgeries, including liver transplant, are performed.
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INTRODUCTION
Carcinoma of  the pancreas is one of  the leading causes 
of  death, with 43140 new cases reported in the United 
States in 2010, which will lead to an estimated 36800 
deaths at a five-year survival of  6%[1]. Amongst differ-
ent treatment options, surgical resection offers the best 
survival outcome to patients with carcinoma of  the head 
of  the pancreas[2]. With the advancement in technology 
and experience sharing, the hospital mortality and mor-
bidity for pancreaticoduodenectomy, also known as the 
Whipple operation, have improved when compared with 
the first report in 1935[3]. However, the surgery remains a 
challenging operation, with hospital mortality rates rang-
ing from 1% to 6% even at experienced centers[4,5]. The 
issue is even more complicated if  the tumor involves 
major vessels around the pancreatic region. The defini-
tion of  borderline resectability is controversial. Although 
many centers have advocated resection of  the tumor 
together with the superior mesenteric vein (SMV) or the 
portal vein (PV), many other centers simply do not con-
sider operation for this group of  patients after balancing 
the risk of  surgery and predicted survival outcomes[6,7].
The aim of  this study was to compare standard pan-
creaticoduodenectomy and pancreaticoduodenectomy 
with simultaneous vascular resection with or without 
vascular reconstruction in terms of  survival outcomes in 
patients who had adenocarcinoma of  the pancreas with 
borderline resectability.
MATERIALS AND METHODS
Study population
From January 2001 to March 2012, 136 patients received 
pancreaticoduodenectomy at Queen Mary Hospital of  
the University of  Hong Kong, China. Of  these, 2.2% 
(3/136) had adenocarcinoma of  the duodenum, 12.5% 
(17/136) had adenocarcinoma of  the common bile duct, 
27.9% (38/136) had adenocarcinoma of  the ampulla of  
Vater, and 57.4% (78/136) had adenocarcinoma of  the 
head of  the pancreas (Figure 1). None of  the patients 
received neoadjuvant chemotherapy before operation.
The study population included the 78 patients with 
adenocarcinoma of  the pancreas. Forty-six of  these 
patients underwent standard pancreaticoduodenectomy 
(group 1), and the remaining 32 patients underwent pan-
creaticoduodenectomy together with vascular resection 
(group 2). The patients’ preoperative data including their 
clinical presentations are listed in Table 1.
Fifty-five patients with unresectable adenocarcinoma 
of  the pancreas without liver metastasis who received 
only bypass surgery (group 3) were selected for additional 
survival comparison. These were patients who were phys-
ically unfit for major pancreaticoduodenectomy or who 
had long-segment arterial encasement by tumors.
Diagnostic imaging
Contrast computed tomography (CT) of  the abdomen 
was performed for all the patients. A tumor was consid-
ered unresectable if  the contrast CT scan showed obvi-
ous extrapancreatic metastasis. Pancreaticoduodenectomy 
was offered to patients with a patent SMV-PV confluence 
despite suspected tumor involvement of  the PV or SMV. 
Operation was also offered to patients with suspected 
tumor involvement of  the short segment of  the superior 
mesenteric artery (SMA). Tumors involving the celiac ar-
tery were considered not suitable for surgical resection.
Surgical technique
All operations were performed by a team of  surgeons 
specialized in hepatobiliary and pancreatic surgery. Con-
ventional or pylorus-preserving pancreaticoduodenec-
tomy was performed according to the decision of  the 
responsible surgeon. Lymph nodes around the head of  
the pancreas, the common hepatic artery and the hepato-
duodenal ligament were dissected. Dissection of  lymph 
nodes around the celiac and SMA regions was performed 
in patients who showed evidence of  lymph node enlarge-
ment. Wedge or segmental resection of  the PV or SMV 
was performed if  a pancreatic head mass was inseparable 
from the vein. The pancreas was dissected from the 
splenic vein to the left of  the mesenteric-portal junction 
and then transected at this level. All tissue around the PV 
and SMV was circumferentially cleared to free the veins 
up to the bifurcation of  the PV and down to the branch-
es of  the SMV. The PV was then sectioned between the 
vascular clamp, and the surgical specimen was removed. 
For segmental resections of  the PV or the SMV shorter 
than 3 cm, end-to-end anastomosis without the use of  a 
graft was possible in all patients in group 2 after adequate 
mobilization of  the SMV and the PV[8]. For segmental 
resections of  the PV or the SMV longer than 3 cm, end-
to-end anastomosis was performed with the use of  a 
vascular conduit. Conduit selections included autologous 
vein, cryo-preserved vein and gortex grafts. The anasto-
mosis was constructed continuously in a single layer with 
6/0 Prolene suture. One third of  the circumference or 
one diameter of  the PV was allowed in the final knotting 
in order to avoid narrowing of  the anastomosis[9]. For 
resection of  the SMA or hepatic artery, the anastomosis 
was performed with the microvascular technique with 
9/0 nylon suture[10].
Pancreaticoduodenectomy anastomosis was per-
formed by an end-to-side, duct-to-mucosa, two-layer 
anastomosis using interrupted fine Prolene sutures. The 
diameter of  the pancreatic duct was measured in every 
case. If  the pancreatic duct was thinner than 2 mm or if  
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the pancreas was considered soft in consistency by the 
operating surgeon, the dunking method without duct-to-
mucosa anastomosis or the double-loop technique was 
employed[11].
Pancreatic stenting was employed if  the pancreatic 
duct was small. For external drainage, depending on the 
size of  the pancreatic duct, an Fr 3-8 polyvinyl catheter 
with multiple side holes was inserted into the pancreatic 
duct. A stent with the largest size that could be put into 
the pancreatic duct was used. Catheter migration was 
prevented by an anchoring stitch that secured the cath-
eter onto the mucosa of  the jejunal side of  the pancre-
aticoduodenectomy anastomosis with a single absorbable 
suture. For internal drainage, an internal drain was put 
across the pancreaticoduodenectomy anastomosis, with 
the tip of  the catheter distal to the anastomosis[12].
After performing the anastomosis, an end-to-side, 
single-layer, interrupted hepaticojejunostomy without 
stenting was performed using the same jejunal loop. A 
single-layer, continuous, hand-sewn antecolic gastrojeju-
nostomy or duodenojejunostomy was then performed, 
with a nasogastric tube placed in the afferent jejunal 
limb of  the anastomosis. No vagotomy, gastrostomy or 
feeding jejunostomy was performed. A drain was placed 
anterior to the pancreaticoduodenectomy anastomosis, 
and another drain was placed posterior to the anastomo-
sis. The vascular reconstruction technique and methods 
of  pancreaticoduodenectomy anastomosis are shown in 
Table 2.
All patients were followed up monthly in the first 
year, and then quarterly if  no recurrence was detected. 
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Table 1  Preoperative clinical parameters
Variables Group 1 Group 2 P  value
(n  = 46) (n  = 32)
Age (yr)   67 (37-82)   63 (35-86) 0.452
Male:female, n 25:21 20:12 0.473
Presence of comorbid illness 25 (54.3) 16 (50.0) 0.705
Cardiovascular disease 15 (32.6)   9 (28.1) 0.673
Pulmonary disease   5 (10.9) 1 (3.1) 0.406
Renal disease 2 (4.3) 1 (3.1) 1.000
Diabetes Mellitus   9 (19.6) 11 (34.4) 0.141
Hemoglobin (g/dL) 12.5 (9.0-15.6) 12.7 (9.5-15.6) 0.614
White blood cell count (× 109/L)   6.9 (3.6-21.2)   6.7 (3.9-13.1) 0.763
Prothrombin time (s) 11.4 (9.8-40.8) 11.3 (9.0-14.4) 0.421
International normalized ratio 1.0 (0.8-3.6) 1.0 (0.8-1.2) 0.938
Serum creatinine (mmol/L)  75 (52-212) 84 (47-143) 0.607
Serum bilirubin ( mmol/L)  102 (5-533)    38 (5-342) 0.020
Albumin (g/L)    39 (27-46) 40.5 (8-47) 0.041
Data are expressed as median (range), or n (%).
Table 2  Operation details  n  (%)
Variables Group 1 Group 2 P  value
(n  = 46) (n  = 32)
Portal vein resection - 18 (56.3) -
Reconstruction method - -
   Primary anastomosis 14 (77.8)
   Cadaveric vein graft   3 (16.7)
   Gortex graft 1 (5.6)
Superior mesenteric vein resection - 22 (68.8) -
Reconstruction method - -
   Primary anastomosis 18 (81.8)
   Cadaveric vein graft   3 (13.6)
   Gortex graft 1 (4.5)
Superior mesenteric artery 
resection
- 3 (9.4) -
Reconstruction method - -
   Primary anastomosis  3 (100)
Pancreaticojejunostomy 
construction method
0.358
   Dunking 1 (2.2) 3 (9.4)
   Duct to mucosa 43 (93.5) 28 (87.5)
   Double loop 2 (4.3) 1 (3.1)
Size of pancreatic duct 0.239
   < 2 mm 1 (2.4)   3 (13.0)
   2-4 mm 15 (36.6)   8 (34.8)
   < 4 mm 25 (61.0) 12 (52.2)
Pancreatic stent 0.882
   No 32 (69.6) 21 (65.6)
   Internal 3 (6.5) 3 (9.4)
   External 11 (23.9)   8 (25.0)
Pancreatico-
duodenectomy
n = 136
CA Pancreas
n  = 78
CA 
Common bile duct
n  = 17
CA Ampulla
n  = 38
CA Duodenum
n = 3
With vascular 
reconstruction
n  = 32
With vascular 
reconstruction
n  = 2
With vascular 
reconstruction
n  = 1
With vascular 
reconstruction
n  = 0
Without vascular 
reconstruction
n  = 46
Without vascular 
reconstruction
n  = 15
Without vascular 
reconstruction
n  = 37
Without vascular 
reconstruction
n  = 3
Figure 1  Distribution of pathologies and pancreaticoduodenectomies for the study population.
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stay of  2 d and a median hospital stay of  17 d, with no 
differences observed in postoperative complications.
The median tumor size for both groups was 3 cm, 
and the majority of  patients had fewer than five lymph 
node metastases (Table 4). There were no differences 
between the groups regarding the method of  pancreati-
cojejunostomy, type of  resection, or disease stage as clas-
sified the American Joint Committee on Cancer (AJCC) 
classification (7th edition)[14].
The one-, three-, and five-year survival rates in group 
1 were 71.1%, 23.6% and 13.5%, respectively (Figure 2A). 
These were not different from group 2, who showed cor-
responding rates of  70.6%, 33.3% and 22.2%. The one-, 
three-, and five-year disease-free survival rates in group 1 
were 48.7%, 15.7% and 15.7%, respectively (Figure 2B), 
which corresponded to 40.3%, 20.2% and 13.4% disease-
free survivals in group 2. 
The one-year survival of  patients in group 3 (stage 
ⅡB/Ⅲ) who had only undergone bypass surgery was 
13.8%, which was significantly lower than in group 2 (P 
< 0.05) (Figure 2C). These patients were either consid-
ered physically unfit for pancreaticoduodenectomy or 
found to have an SMA encasement larger than 2 cm dur-
ing laparotomy. Patients with liver metastasis and distant 
metastasis were not included in this group. 
Patients were classified into early and advanced 
groups for survival comparison according to the pres-
ence of  lymph node metastasis. The early group was 
comprised of  patients with stage ⅠA, ⅠB or ⅡA disease. 
The advanced group was comprised of  patients with 
disease stage ⅡB or Ⅲ. The median survival durations 
for group 1 and group 2 patients with early disease were 
CT was performed one month after the operation, 
quarterly in the first year, and half-yearly subsequently. 
Pancreatic fistula was classified into type A, B and C ac-
cording to the International Study Group of  Pancreatic 
Fistula[13]. Recurrence was defined as the presence of  
typical features appearing on CT or magnetic resonance 
imaging scans on follow-up. If  necessary, recurrence was 
confirmed by cytology. Patients were referred to medical 
oncologists for consideration for adjuvant chemotherapy 
after the surgery.
Statistical analysis
The baseline characteristics of  patients are expressed as 
median and range or n and percent. The Mann-Whitney 
U test was used to compare continuous variables, and 
Pearson’s χ 2 test was used to compare discrete variables. 
Survival analysis was performed on the time of  disease-
free survival vs tumor recurrence or death. Survival curves 
were computed with the Kaplan-Meier method and com-
pared between groups by the log-rank test. Significance 
was defined as P < 0.05. All statistical calculations were 
made with the computer software SPSS/PC+ (SPSS Inc., 
Chicago, IL, United States).
RESULTS
The medians for volume of  blood loss (1200 mL vs 800 
mL; P < 0.05) and operation time (715 min vs 580 min; P 
< 0.05) were significantly greater in group 2 compared to 
group 1 (Table 3). Both groups had an intensive care unit 
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Table 3  Short-term outcomes
Variables Group 1 Group 2 P  value
(n= 46) (n  = 32)
Blood loss (mL) 800 (250-1600) 1200 (100-5000)   0.007
Operation time (min) 580 (378-855) 715 (487-992) < 0.0001
Hospital stay (d)    17 (9-120)   17 (11-89)   0.316
Intensive care unit stay (d)   2 (1-10)   2 (0-24)   0.847
Hospital death 2 (4.3) 1 (3.1)   1.000
Patients with complication 20 (43.5) 10 (31.3)   0.275
   Chest infection 3 (6.5) 2 (6.3)   1.000
   Pleural effusion 1 (2.2) 1 (3.1)   1.000
   Wound infection   7 (15.2) 1 (3.1)   0.176
   Subphrenic abscess or 
   collection
  5 (10.9) 1 (3.1)   0.406
   Intra-abdominal bleeding 1 (2.2) 0 (0.0)   1.000
   Gastrointestinal bleeding 1 (2.2) 1 (3.1)   1.000
   Cardiac arrhythmia 4 (8.7) 2 (6.3)   1.000
   Acute coronary syndrome 2 (4.3) 1 (3.1)   1.000
   Deep vein thrombosis 2 (4.3) 0 (0.0)   0.641
   Delayed gastric emptying 
   (> 7 d)
3 (6.5)   5 (15.6)   0.355
Types of pancreatic fistula 
according to ISGPF
  0.662
All types 10 (21.7)   5 (15.6)
   Type A   6 (13.0)   4 (12.5)
   Type B 3 (6.5)   1 (3.13)
   Type C 1 (2.2) 0 (0.0)
Data are expressed as median (range), or n (%). ISGPF: International Study 
Group on Pancreatic Fistula.
Table 4  Pathologic examination results
Variables Group 1 Group 2 P  value
(n  = 46) (n  = 32)
Tumor size (cm)       3 (1.0-8.0)       3 (1.6-6.0) 0.315
Lymph node metastases 0.299
   No 21 (45.7) 12 (37.5)
   < 5 22 (47.8) 15 (46.9)
   5-10 2 (4.3)   5 (15.6)
   > 10 1 (2.2) 0 (0.0)
Pancreaticojejunostomy 
construction method
0.613
   Dunking or other   4 (12.5) 3 (6.5)
   Duct to mucosa 28 (87.5) 43 (93.5)
R0 resection 35 (75.6) 25 (78.1) 0.793
R1 resection 11 (24.4)   7 (21.9)
AJCC staging (7th edition) 0.981
   Stage ⅠA 2 (4.3) 2 (6.3)
   Stage ⅠB 4 (8.7) 3 (9.4)
   Stage ⅡA 14 (30.4)   8 (25.0)
   Stage ⅡB 25 (54.3) 18 (56.3)
   Stage Ⅲ 1 (2.2) 1 (3.1)
Stage ⅠA/ⅠB/ⅡA 
(no lymph node involvement)
20 (43.5) 13 (40.6) 0.802
Stage ⅡB/Ⅲ (advanced) 26 (56.5) 19 (59.4)
Data are expressed as median (range), or n (%). AJCC: American Joint 
Committee on Cancer. 
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similar at 28.8 and 27.5 mo, respectively, and 15.8 and 
17.1 mo for advanced disease stages (Figure 2D).
Sixteen factors that might affect patient survival after 
pancreaticoduodenectomy were identified (Table 5). Mul-
tivariate analysis showed that only lymph node metastasis 
was significant for poorer survival (P = 0.021), whereas 
a univariate analysis identified AJCC disease stage as the 
only significant factor.
DISCUSSION
Pancreaticoduodenectomy is a technically challenging 
procedure, and the rate of  morbidities (including pancre-
atic fistula) ranges between 15% and 50%[15,16]. A gradual 
decrease in mortality has been observed in recent years, 
though the patient age and the incidence of  comorbid ill-
ness have increased. It is generally agreed that a hospital 
mortality rate of  3%-5% is acceptable for pancreatico-
duodenectomy without vascular resection at high-volume 
centers[4]. However, it is believed that the risk of  this 
operation is high if  simultaneous vascular resection with 
reconstruction is required. Many surgeons have taken a 
more conservative approach when the tumor is consid-
ered barely resectable[17,18].
Tumor invasion of  the PV or SMV is considered 
a sign of  advanced disease, which is likely to result in 
poor surgical outcomes. Thus, many centers adopt more 
conservative approaches for patients with vascular inva-
sion[19]. In this study, we found that tumor invasion or 
dense adhesion to the PV or SMV did not correlate with 
the stage of  disease. The median tumor size was 3 cm in 
both groups, but tumors as small as 1.6 cm could have 
invaded the PV or SMV, necessitating vascular resection. 
It is tumor location rather than tumor size that affects 
surgical planning. Fuhrman et al[20] described a similar ob-
servation in 23 patients whose tumors with a median size 
of  3 cm led to major vessel involvement.
Due to the retrospective design of  this study, we did 
not present the degree of  invasion of  the PV or SMV 
found by histopathologic examinations. Since histologic 
information can only be obtained after surgery, an op-
erating surgeon has to judge during laparotomy whether 
there is genuine vascular invasion and whether simultane-
ous vascular resection is required. At centers experienced 
in vascular reconstruction, simultaneous resection for 
suspected venous invasion should be performed. The 
AJCC has not considered tumor invasion of  the PV or 
SMV a factor affecting tumor staging, and therefore a tu-
mor with PV or SMV involvement is classified stage ⅡA 
if  there is no lymph node metastasis. In accordance with 
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Figure 2  Comparison of survival rates. A: Overall and B: Disease-free survival curves for patients in group 1 and group 2; C: Overall survival curves for patients in 
group 2 and group 3; D: Stage-specific survival curves for group 1 and group 2 patients; Group 1a and 2A: Stage Ⅰ and ⅡA disease; Group 1b and 2b: Stage ⅡB 
and Ⅲ disease.
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P = 0.815 P  = 0.589
Group 1 (n  = 46)
Group 2 (n  = 32)
Group 1 (n  = 44)
Group 2 (n  = 31)
this, patients with tumor invasion of  the PV or SMV are 
still considered to have a relatively early-stage cancer. This 
might be quite contradictory to many clinicians’ concepts.
The definition of  borderline resectability for pan-
creatic cancer remains controversial. Varadhachary et 
al[21] proposed three categories of  patients with tumors 
with borderline resectability: types A, B and C. Type-A 
patients have tumors with one or more of  the following 
three findings on CT images: (1) tumor abutment (≤ 
180° of  the circumference of  the vessel) of  the SMA or 
celiac axis; (2) tumor abutment or encasement (> 180° 
of  the circumference of  the vessel) of  a short segment 
of  the hepatic artery, typically at the origin of  the gas-
troduodenal artery; and (3) tumor-related occlusion of  a 
short segment of  the SMV, PV, or SMV-PV confluence 
that is amenable to vascular resection and reconstruction 
because of  a patent SMV and PV below and above the 
area of  occlusion. Type-B patients have tumors with ex-
trapancreatic metastasis. Type-C patients are patients who 
have marginal physical fitness for major operations.
In fact, many patients with adenocarcinoma of  the 
pancreas can have a relatively early cancer stage even if  
they are classified as a type-A patient. The decision on 
treatment strategy for these patients depends on the 
risk and benefit of  surgery and whether or not there is a 
good alternative treatment. Neoadjuvant chemotherapy 
has been suggested to increase the resection rate. Che-
motherapy or chemoradiation have a partial tumor re-
sponse rate of  56%[22]. Although it might be effective for 
some patients, subjecting every patient with SMV or PV 
involvement to neoadjuvant therapy without considering 
upfront surgery would allow progression of  cancer in 
40% of  patients who would not respond well.
This study shows that pancreaticoduodenectomy with 
vascular resection can be performed safely at centers 
with experience and expertise. The complication and 
pancreatic fistula rates in group 2 were not inferior to 
those in group 1. No SMV or PV thrombosis was found 
in the study. The experience and techniques in vessel 
reconstruction we have learned from our liver transplant 
program can be transferred to many complicated hepa-
tobiliary and pancreatic surgeries[10,23,24]. Techniques used 
in reconstruction of  the PV, SMV or SMA are identical 
to those used in liver transplantation. Most of  the time, 
PV or SMV reconstruction is possible without generat-
ing tension on the venous anastomosis after a Cattell-
Braasch maneuver[25]. When simultaneous resection of  a 
PV longer than 5 cm is required during pancreaticoduo-
denectomy, cadaveric vein grafts available from the liver 
transplant program give extra flexibility for the vascular 
reconstruction.
Contrast CT is one of  the most sensitive ways for 
preoperative staging of  pancreatic cancer[26,27]. It has been 
suggested that the morphologic features of  portal vein 
invasion could predict the survival outcomes of  patients. 
Patients with extensive tumor involvement of  the ves-
sel would have poorer survival[27,28]. Likewise, possible 
regional lymph node metastases can now be revealed by 
fine-cut CT scans. Regional lymph node metastases are 
associated with poor patient survival. However, these so-
called poor prognostic indicators should only be regarded 
as a prognostic suggestion before surgery, and should 
not become an absolute contraindication to surgery, as 
surgical resection provides the best survival outcomes for 
patients with barely resectable diseases. Pancreatic cancer 
with arterial invasion is also associated with poor patient 
survival. In a previous study, patients who had pancreati-
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Table 5  Univariate analyses of factors affecting survival 
outcomes
Factor Median survival (mo) P  value
Median age (yr) 0.634
   ≤ 64 (n = 40) 22.35 ± 3.73
   > 64 (n = 38) 15.84 ± 4.40
Sex 0.445
   Male (n = 45) 22.35 ± 6.32
   Female (n = 33) 19.26 ± 3.74
Comorbidity 0.890
   No (n = 37) 20.05 ± 4.08
   Yes (n = 41) 21.36 ± 4.34
Preoperative cholangitis 0.487
   No (n = 76) 19.26 ± 3.54
   Yes (n = 2) 21.36
Postoperative complication 0.204
   No (n = 48) 23.79 ± 5.26
   Yes (n = 30) 16.76 ± 4.18
International normalized ratio 0.924
   ≤ 1 (n = 55) 21.36 ± 2.79
   > 1 (n = 15) 27.51 ± 14.53
Creatinine level (mmol/L) 0.652
   ≤ 79 (n = 37) 23.79 ± 4.42
   > 79 (n = 36) 13.90 ± 2.98
Total bilirubin level ( mmol/L) 0.581
   ≤ 72 (n = 39) 22.35 ± 3.16
   > 72 (n = 38) 16.66 ± 5.01
Serum albumin level (g/L) 0.419
   ≤ 40 (n = 44) 28.79 ± 8.12
   > 40 (n = 29) 19.09 ± 3.77
Blood loss (mL) 0.284
   ≤ 850 (n = 36) 28.79 ± 5.84
   > 850 (n = 33) 21.36 ± 4.89
Tumor Size (cm) 0.630
   ≤ 3 (n = 43) 16.76 ± 3.22
   > 3 (n = 28) 19.09 ± 7.97
R1 resection 0.055
   No (n = 59) 25.34 ± 5.32
   Yes (n = 18) 13.44 ± 3.87
Lymph node metastases 0.113
   No (n = 33) 28.79 ± 3.82
   < 5 (n = 37) 17.12 ± 3.05
   5-10 (n = 7) 11.40 ± 5.68
   > 10 (n = 1) 22.18
Disease stage (AJCC staging, 7th edition) 0.036
   Early (ⅠA + ⅠB + ⅠC) (n = 33) 28.79 ± 5.00
   Advanced (ⅡB + Ⅲ + Ⅳ) (n = 45) 17.12 ± 3.41
Simultaneous vascular resection 0.815
   Yes (n = 32) 21.36 ± 5.93
   No (n = 46) 19.26 ± 3.58
Pancreatic fistula type (according to ISGPF) 0.488
   No fistula + type A (n = 73) 20.05 ± 3.43
   Type B + type C (n = 5) 13.90 ± 6.61
Data are presented as mean ± SE. AJCC: American Joint Committee on 
Cancer; ISGPF: International Study Group on Pancreatic Fistula.
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coduodenectomy with simultaneous arterial resection had 
a median overall survival duration of  only 15.8 mo[29]. 
In our present study, patients having only bypass 
surgery with palliative intention (group 3) were included 
for comparison. Many of  these patients were not sub-
jected to pancreaticoduodenectomy because they were 
not physically fit for major surgery. In terms of  survival, 
these patients fared far worse than group 2 patients. Ap-
proximately 23% of  the patients in the study had R1 re-
section as shown by final pathologic examination. Many 
of  these patients had posterior margin involvement. No 
difference in the distribution of  margin involvement was 
found between group 1 and group 2. As there is no as-
sociation between SMV or PV invasion and R1 resection, 
and the degree of  posterior margin involvement cannot 
be known before laparotomy, patients should not be 
denied pancreaticoduodenectomy on the basis of  CT im-
ages of  vascular invasion.
Adenocarcinoma of  the pancreas is a cancer with 
poor patient survival. Surgical resection provides the best 
chance of  cure. Pancreaticoduodenectomy with simulta-
neous vascular resection is a safe and effective treatment 
option. The postoperative morbidity and pancreatic 
fistula rates are not inferior at centers with expertise. In 
patients who suffer from adenocarcinoma of  the pan-
creas with portal venous invasion, survival after this com-
plicated procedure is not compromised when compared 
with that after standard pancreaticoduodenectomy.
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